Intersect ENT, Inc. (NASDAQ:XENT) Shares Purchased by Verition Fund Management LLC

Verition Fund Management LLC lifted its holdings in Intersect ENT, Inc. (NASDAQ:XENTGet Rating) by 26.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,673 shares of the medical equipment provider’s stock after purchasing an additional 7,261 shares during the quarter. Verition Fund Management LLC’s holdings in Intersect ENT were worth $971,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its position in shares of Intersect ENT by 2,036.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,111 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 1,059 shares in the last quarter. PenderFund Capital Management Ltd. acquired a new stake in shares of Intersect ENT in the 1st quarter worth $172,000. Diametric Capital LP acquired a new stake in shares of Intersect ENT in the 4th quarter worth $232,000. GSA Capital Partners LLP purchased a new position in Intersect ENT in the 1st quarter worth $364,000. Finally, Virtu Financial LLC purchased a new position in Intersect ENT in the 1st quarter worth $396,000. Institutional investors and hedge funds own 92.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Intersect ENT in a research note on Thursday. They issued a “sell” rating for the company.

Intersect ENT Stock Performance

Shares of XENT stock opened at $28.24 on Thursday. The firm has a market capitalization of $954.91 million, a price-to-earnings ratio of -5.90 and a beta of 1.45. The company has a debt-to-equity ratio of 6.89, a current ratio of 1.88 and a quick ratio of 1.50. The business has a fifty day moving average of $28.24 and a 200 day moving average of $28.09. Intersect ENT, Inc. has a 1 year low of $15.92 and a 1 year high of $28.25.

Intersect ENT Profile

(Get Rating)

Intersect ENT, Inc operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Featured Stories

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT, Inc. (NASDAQ:XENTGet Rating).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.